Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole

Tatiana M. Prowell, Amanda L. Blackford, Celia Byrne, Nagi F. Khouri, Mitchell Dowsett, Elizabeth Folkerd, Karineh S. Tarpinian, Pendleton P. Powers, Laurie A. Wright, Michele G. Donehower, Stacie C. Jeter, Deborah K. Armstrong, Leisha A. Emens, John H. Fetting, Antonio C. Wolff, Elizabeth Garrett-Mayer, Todd Skaar, Nancy E. Davidson, Vered Stearns

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Factors associated with an increased risk of breast cancer include prior breast cancer, high circulating estrogens, and increased breast density. Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer. We conducted a prospective, single-arm, single-institution study to determine whether use of anastrozole is associated with changes in contralateral breast density and circulating estrogens. Eligible patients included postmenopausal women with hormone receptor-positive early-stage breast cancer who had completed local therapy, had an intact contralateral breast, and were recommended an aromatase inhibitor as their only systemic therapy. Participants received anastrozole 1 mg daily for 12 months on study. We assessed contralateral breast density and serum estrogens at baseline, 6, and 12 months. The primary endpoint was change in contralateral percent breast density from baseline to 12 months. Secondary endpoints included change in serum estrone sulfate from baseline to 12 months. Fiftyfour patients were accrued. At 12 months, compared with baseline, there was a nonstatistically significant reduction in breast density (mean change: - 16%, 95% CI: - 30 to 2, P=0.08) and a significant reduction in estrone sulfate (mean change: - 93%, 95% CI: - 94 to - 91, P < 0.001). Eighteen women achieved 20% or greater relative reduction in contralateral percent density at 12 months compared with baseline; however, no measured patient or disease characteristics distinguished these women from the overall population. Large trials are required to provide additional data on the relationship between aromatase inhibitors and breast density and, more importantly, whether observed changes in breast density correlate with meaningful disease-specific outcomes.

Original languageEnglish
Pages (from-to)1993-2001
Number of pages9
JournalCancer Prevention Research
Volume4
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Estrogens
Aromatase Inhibitors
Breast Neoplasms
anastrozole
Breast Density
Serum
Breast
Hormones
Incidence
Therapeutics
Population
estrone sulfate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prowell, T. M., Blackford, A. L., Byrne, C., Khouri, N. F., Dowsett, M., Folkerd, E., ... Stearns, V. (2011). Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prevention Research, 4(12), 1993-2001. https://doi.org/10.1158/1940-6207.CAPR-11-0154

Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. / Prowell, Tatiana M.; Blackford, Amanda L.; Byrne, Celia; Khouri, Nagi F.; Dowsett, Mitchell; Folkerd, Elizabeth; Tarpinian, Karineh S.; Powers, Pendleton P.; Wright, Laurie A.; Donehower, Michele G.; Jeter, Stacie C.; Armstrong, Deborah K.; Emens, Leisha A.; Fetting, John H.; Wolff, Antonio C.; Garrett-Mayer, Elizabeth; Skaar, Todd; Davidson, Nancy E.; Stearns, Vered.

In: Cancer Prevention Research, Vol. 4, No. 12, 12.2011, p. 1993-2001.

Research output: Contribution to journalArticle

Prowell, TM, Blackford, AL, Byrne, C, Khouri, NF, Dowsett, M, Folkerd, E, Tarpinian, KS, Powers, PP, Wright, LA, Donehower, MG, Jeter, SC, Armstrong, DK, Emens, LA, Fetting, JH, Wolff, AC, Garrett-Mayer, E, Skaar, T, Davidson, NE & Stearns, V 2011, 'Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole', Cancer Prevention Research, vol. 4, no. 12, pp. 1993-2001. https://doi.org/10.1158/1940-6207.CAPR-11-0154
Prowell, Tatiana M. ; Blackford, Amanda L. ; Byrne, Celia ; Khouri, Nagi F. ; Dowsett, Mitchell ; Folkerd, Elizabeth ; Tarpinian, Karineh S. ; Powers, Pendleton P. ; Wright, Laurie A. ; Donehower, Michele G. ; Jeter, Stacie C. ; Armstrong, Deborah K. ; Emens, Leisha A. ; Fetting, John H. ; Wolff, Antonio C. ; Garrett-Mayer, Elizabeth ; Skaar, Todd ; Davidson, Nancy E. ; Stearns, Vered. / Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. In: Cancer Prevention Research. 2011 ; Vol. 4, No. 12. pp. 1993-2001.
@article{b686b8f65577413cb63de548a1fc4679,
title = "Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole",
abstract = "Factors associated with an increased risk of breast cancer include prior breast cancer, high circulating estrogens, and increased breast density. Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer. We conducted a prospective, single-arm, single-institution study to determine whether use of anastrozole is associated with changes in contralateral breast density and circulating estrogens. Eligible patients included postmenopausal women with hormone receptor-positive early-stage breast cancer who had completed local therapy, had an intact contralateral breast, and were recommended an aromatase inhibitor as their only systemic therapy. Participants received anastrozole 1 mg daily for 12 months on study. We assessed contralateral breast density and serum estrogens at baseline, 6, and 12 months. The primary endpoint was change in contralateral percent breast density from baseline to 12 months. Secondary endpoints included change in serum estrone sulfate from baseline to 12 months. Fiftyfour patients were accrued. At 12 months, compared with baseline, there was a nonstatistically significant reduction in breast density (mean change: - 16{\%}, 95{\%} CI: - 30 to 2, P=0.08) and a significant reduction in estrone sulfate (mean change: - 93{\%}, 95{\%} CI: - 94 to - 91, P < 0.001). Eighteen women achieved 20{\%} or greater relative reduction in contralateral percent density at 12 months compared with baseline; however, no measured patient or disease characteristics distinguished these women from the overall population. Large trials are required to provide additional data on the relationship between aromatase inhibitors and breast density and, more importantly, whether observed changes in breast density correlate with meaningful disease-specific outcomes.",
author = "Prowell, {Tatiana M.} and Blackford, {Amanda L.} and Celia Byrne and Khouri, {Nagi F.} and Mitchell Dowsett and Elizabeth Folkerd and Tarpinian, {Karineh S.} and Powers, {Pendleton P.} and Wright, {Laurie A.} and Donehower, {Michele G.} and Jeter, {Stacie C.} and Armstrong, {Deborah K.} and Emens, {Leisha A.} and Fetting, {John H.} and Wolff, {Antonio C.} and Elizabeth Garrett-Mayer and Todd Skaar and Davidson, {Nancy E.} and Vered Stearns",
year = "2011",
month = "12",
doi = "10.1158/1940-6207.CAPR-11-0154",
language = "English",
volume = "4",
pages = "1993--2001",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole

AU - Prowell, Tatiana M.

AU - Blackford, Amanda L.

AU - Byrne, Celia

AU - Khouri, Nagi F.

AU - Dowsett, Mitchell

AU - Folkerd, Elizabeth

AU - Tarpinian, Karineh S.

AU - Powers, Pendleton P.

AU - Wright, Laurie A.

AU - Donehower, Michele G.

AU - Jeter, Stacie C.

AU - Armstrong, Deborah K.

AU - Emens, Leisha A.

AU - Fetting, John H.

AU - Wolff, Antonio C.

AU - Garrett-Mayer, Elizabeth

AU - Skaar, Todd

AU - Davidson, Nancy E.

AU - Stearns, Vered

PY - 2011/12

Y1 - 2011/12

N2 - Factors associated with an increased risk of breast cancer include prior breast cancer, high circulating estrogens, and increased breast density. Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer. We conducted a prospective, single-arm, single-institution study to determine whether use of anastrozole is associated with changes in contralateral breast density and circulating estrogens. Eligible patients included postmenopausal women with hormone receptor-positive early-stage breast cancer who had completed local therapy, had an intact contralateral breast, and were recommended an aromatase inhibitor as their only systemic therapy. Participants received anastrozole 1 mg daily for 12 months on study. We assessed contralateral breast density and serum estrogens at baseline, 6, and 12 months. The primary endpoint was change in contralateral percent breast density from baseline to 12 months. Secondary endpoints included change in serum estrone sulfate from baseline to 12 months. Fiftyfour patients were accrued. At 12 months, compared with baseline, there was a nonstatistically significant reduction in breast density (mean change: - 16%, 95% CI: - 30 to 2, P=0.08) and a significant reduction in estrone sulfate (mean change: - 93%, 95% CI: - 94 to - 91, P < 0.001). Eighteen women achieved 20% or greater relative reduction in contralateral percent density at 12 months compared with baseline; however, no measured patient or disease characteristics distinguished these women from the overall population. Large trials are required to provide additional data on the relationship between aromatase inhibitors and breast density and, more importantly, whether observed changes in breast density correlate with meaningful disease-specific outcomes.

AB - Factors associated with an increased risk of breast cancer include prior breast cancer, high circulating estrogens, and increased breast density. Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer. We conducted a prospective, single-arm, single-institution study to determine whether use of anastrozole is associated with changes in contralateral breast density and circulating estrogens. Eligible patients included postmenopausal women with hormone receptor-positive early-stage breast cancer who had completed local therapy, had an intact contralateral breast, and were recommended an aromatase inhibitor as their only systemic therapy. Participants received anastrozole 1 mg daily for 12 months on study. We assessed contralateral breast density and serum estrogens at baseline, 6, and 12 months. The primary endpoint was change in contralateral percent breast density from baseline to 12 months. Secondary endpoints included change in serum estrone sulfate from baseline to 12 months. Fiftyfour patients were accrued. At 12 months, compared with baseline, there was a nonstatistically significant reduction in breast density (mean change: - 16%, 95% CI: - 30 to 2, P=0.08) and a significant reduction in estrone sulfate (mean change: - 93%, 95% CI: - 94 to - 91, P < 0.001). Eighteen women achieved 20% or greater relative reduction in contralateral percent density at 12 months compared with baseline; however, no measured patient or disease characteristics distinguished these women from the overall population. Large trials are required to provide additional data on the relationship between aromatase inhibitors and breast density and, more importantly, whether observed changes in breast density correlate with meaningful disease-specific outcomes.

UR - http://www.scopus.com/inward/record.url?scp=83055174670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055174670&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-11-0154

DO - 10.1158/1940-6207.CAPR-11-0154

M3 - Article

C2 - 21885816

AN - SCOPUS:83055174670

VL - 4

SP - 1993

EP - 2001

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 12

ER -